2QFY21 marked initial signs of volume recovery, the benefit of mix, and costcutting initiatives coming together. This coupled with normalcy in working capital as well as tight control on capex resulted in FCF turning positive. JLR's near-term volumes may be at risk from a potential second wave of COVID. However, mix improvement and tight cost/capex control would drive sharp improvement in operating performance and debt reduction. We upgrade our FY22E EPS by 13% to factor in lower tax in JLR (reversal of deferred tax). Maintain Buy, with TP of INR230 (Sep'22 SOTP)....